Actively hiring
Clinical Trial Services (CRO)
CRO & CDMO Services
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$20.3M
3 rounds on record
Latest round
$5M
Venture round · Jul 2024 · 2 yr ago
Hiring now
2
+1 posted in 30 days
Backers
1
Ampersand Capital Partners
The money's age
Long since its last round
27 months since the last round · and hiring
Momentum
13/100
hiring for its size
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 16, 2024
New executive Peter Glick, Executive Officer, Director · SEC Form D
Jul 1, 2024
Raised a round Venture round $5M · SEC Form D
Mar 3, 2023
Raised a round Venture round $6M · SEC Form D
Aug 9, 2021
Raised a round Venture round $9.3M · SEC Form D
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2024 | $5M | — | SEC Form D |
| Venture round | Mar 2023 | $6M | — | SEC Form D |
| Venture round | Aug 2021 | $9.3M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Meadowhawk Biolabs, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Glick PeterExecutive Officer, DirectorSEC Form D
Jessica SullivanExecutive OfficerSEC Form D
James JerseyExecutive Officer, DirectorSEC Form D
Peter GlickExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one

backs Lindus Health

backs Lindus Health
Similar startupsby what they do, their industry and backers

Science-driven, results-focused BIOTECH & CRO Pikralida to firma biotechnologiczna, która łączy działalność badawczo-rozwojową (R&D) z…

Viral vector CDMO delivering AAV, lentiviral and retroviral vector manufacturing for cell and gene therapy developers from preclinical to…

Advance translational oncology with Crown Bioscience, a full-service CRO delivering comprehensive preclinical and oncology CRO services…

The Innovation CRO. Curavit partners with a variety of sponsors to design and execute innovative clinical trials, leveraging our Virtual…

Lindus Health is an artificial intelligence native contract research organisation that runs clinical trials end to end. Founded in 2021 in…

Allucent is a contract research organization that runs clinical trials for small and mid-sized biotechnology and pharmaceutical companies…
Salary insights
Compensation ranges based on this company's open jobs
Median
$103k
Typical range
$65k – $140k
Open positions
2
1
Jobs
Principal
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Principal | 1 | $140k | $140k |
Highest paying role
Principal Scientist I - LCMS
$140k
Normalized to USD per year
People

Glick Peter
Executive Officer, Director

Jessica Sullivan
Executive Officer

James Jersey
Executive Officer, Director

Peter Glick
Executive Officer, Director

Herbert Hooper
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
28/100
Slowing
Open positions
2
0 opened / 0 closed in 30 days
ATS activity
Every ~5 hours
Today
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▲
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
1
Countries
1
Busiest office
Marlborough
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Marlborough
United States
HQ
2 open roles 2 posted in 90 days 100% engineering $103k Avg Salary
hires for Science & Research
33 Locke Drive, Suite 102, Marlborough, MA, 01752, US
San Francisco
United States
Regional office
San Francisco
26229 Eden Landing Road, Hayward, CA 94545
Boston
United States
Regional office
Boston
33 Locke Drive, Suite 102, Marlborough, MA 01752

Ampersand Capital Partners 


